source
- Ascletis oral GLP-1 candidate ASC30 meets primary and secondary goals in phase 2 diabetes studyAscletis reported that its oral GLP-1 small‑molecule candidate ASC30 achieved both its primary and secondary endpoints in a phase 2 trial involving 100 patients with type 2 diabetes. The study sho…
- Medline orders removal of all brand beds and accessories over fire and asphyxiation hazardsMedline has issued an urgent field safety notice indicating that all of its branded hospital beds and related components must be removed or corrected because of identified safety risks. The FDA’s…